Drug Profile
ISTH 0036
Alternative Names: ISTH-0036; TGF-Β2 isoform specific antisense oligonucleotide - Isarna TherapeuticsLatest Information Update: 29 Jul 2023
Price :
$50
*
At a glance
- Originator Isarna Therapeutics
- Class Antiglaucomas; Antisense oligonucleotides; Eye disorder therapies
- Mechanism of Action RNA interference; Transforming growth factor beta2 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic macular oedema; Wet age-related macular degeneration
- Phase I Open-angle glaucoma
- Preclinical Cancer; Dry age-related macular degeneration
Most Recent Events
- 20 Jul 2023 Preclinical trials in Cancer in Germany (Parenteral) (Isarna Therapeutics pipeline; July 2023)
- 16 May 2023 ISTH 0036 is still in phase-I clinical trial in Open angle glaucoma in Germany (Intravitreous) (Isarna Therapeutics pipeline, May 2023)
- 16 May 2023 Preclinical trials in Dry age-related macular degeneration in Germany, prior to May 2023 (unspecified) (Isarna Therapeutics pipeline, May 2023)